



KINEXUS

Kinexus Bioinformatics Corporation is Pleased to Announce the Appointment of Three New Directors to the Board

Senior Biotechnology Executives Bring Diverse Expertise to the Board of Kinexus

FOR IMMEDIATE RELEASE JULY 1, 2000

VANCOUVER, British Columbia - Dr. Steven Pelech, President and CEO of Kinexus Bioinformatics Corporation is pleased to announce the appointment of Dr. Donald Rix, Dr. Edwin Levy and Mr. Scott Cormack to the Board of Directors of Kinexus.

Dr. Rix is an active member of the biotechnology industry, having served on the boards of many organizations. He is presently Chairman of the Board of Directors of MDS Metro Laboratories, Chairman and Director of the Board of BioFuture Fund, and he is one of the owners and founders of Cantest Industry Laboratory. He has also served on the Science Council of BC, BC Medical Research Foundation grant committees as well as a director of various biotechnology companies. His other honorable achievements include an Honorary Diploma of Technology from the British Columbia Institute of Technology (1985), an Honorary Degree in Science and Technology from the University of Western Ontario (1998), and a Fellowship in General Pathology (FRCP) Canada.

Mr. Cormack has successfully led the development of biotechnology products from the lab bench through pre-clinical development to clinical trials in the areas of oncology, vaccines and immunotherapy. Mr. Cormack is currently the Vice President of Milestone Medica Corporation, and is responsible for assessing, closing and managing investments in life sciences in Western Canada. In addition to his position at Milestone, Mr. Cormack is President and CEO of two biotechnology companies, a member of the University of Alberta Industry Liaison Offices' Advisory Board, and is currently a member of the Board of Directors of four biotechnology companies.

Dr. Levy joined QLT, Inc. thirteen years ago to work in regulatory affairs and project management before his appointment to Vice President, Corporate Development in 1993, and more recently to Senior Vice President, Corporate Development. He is responsible for establishing QLT's strategic alliances and oversees the intellectual property and legal departments. Dr. Levy is also a Director of the Board of Bio FutureFund, Adherex, and BIOTECCanada

Kinexus is harnessing the powerful synergies of genomics, proteomics, and bioinformatics to understand cell signalling for the advancement of drug discovery, disease diagnosis, and global biomedical research.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.

PRESS RELEASE - 2000 JULY 1